2-Propoxypropan-1-amine

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2-Propoxypropan-1-amine
• 化学式: C₆H₁₅NO
• 分子量: 117.19
• InChiKey: ZYSOCEMLXONWAC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.5
• 重原子数：
  8
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• [EN] NOVEL MODULATORS OF CELL CYCLE CHECKPOINTS AND THEIR USE IN COMBINATION WITH CHECKPOINT KINASE INHIBITORS<br/>[FR] NOUVEAUX MODULATEURS DE POINTS DE CONTRÔLE DU CYCLE CELLULAIRE ET LEUR UTILISATION EN COMBINAISON AVEC DES INHIBITEURS DE KINASE DE POINT DE CONTRÔLE
  申请人：SCHERING CORP

  公开号：WO2009061781A1

  公开（公告）日：2009-05-14

  In its many embodiments, the present invention provides a novel class of pyrimidine analogs of formula (V) as targeted mechanism-based modulators of cell cycle checkpoints. Cancers and/or malignancies can be treated by administration of a cell cycle checkpoint modulator of the invention. Also discussed are suitable combinations of the cell cycle checkpoint modulator with a checkpoint kinase inhibitor to produce synergistic apoptosis in cancer cells. The invention includes methods of treating cancers by administering the combination of the cell cycle checkpoint modulator and the checkpoint kinase inhibitor, pharmaceutical compositions comprising the activator as well as the combination and pharmaceutical kits.

  在其多种实施方式中，本发明提供了一类新型的嘧啶类似物，其化学式为（V），作为细胞周期检查点的靶向机制调节剂。可以通过给予本发明的细胞周期检查点调节剂来治疗癌症和/或恶性肿瘤。还讨论了适当的细胞周期检查点调节剂与检查点激酶抑制剂的组合，以在癌细胞中产生协同凋亡。该发明包括通过给予细胞周期检查点调节剂和检查点激酶抑制剂的组合来治疗癌症的方法，以及包含激活剂以及该组合的药物组合和药物配套工具。
• Quinoline derivative and use of same
  申请人：MITSUI TOATSU CHEMICALS, Inc.

  公开号：EP0818512A1

  公开（公告）日：1998-01-14

  Quinoline compound, zinc halogenide complex and zinc complex suited for use in an electro-luminescence element, a fluorescent material and an ultraviolet absorption material, and a preparation process for these compounds are described. These compounds and a tautomer of the same has a strong luminescent intensity and is used for an EL material, the compound of zinc halogenide complex and zinc complex and a tautomer of the same has absorption at a wave length of 400nm or less and is used for an ultraviolet absorption material, and further the quinoline compound and a tautomer has a strong luminescent intensity and is used for a fluorescent material. The zinc halogenide complex and zinc complex can be prepared by each other related preparation processes directly from a quinoline derivative and a phthalimide derivative, or by way of the quinoline compound which is obtained from these derivatives.

  描述了适用于电致发光元件、荧光材料和紫外线吸收材料的喹啉化合物、卤化锌络合物和锌络合物，以及这些化合物的制备工艺。 这些化合物及其同系物具有很强的发光强度，可用于电致发光材料；卤化锌络合物和锌络合物的化合物及其同系物在波长为 400nm 或以下时有吸收，可用于紫外线吸收材料；此外，喹啉化合物及其同系物具有很强的发光强度，可用于荧光材料。 卤化锌络合物和锌络合物可以直接从喹啉衍生物和邻苯二甲酰亚胺衍生物，或通过从这些衍生物中得到的喹啉化合物，通过彼此相关的制备工艺制备。
• Nucleic acid ligand complexes
  申请人：Gilead Sciences, Inc.

  公开号：EP2168973A1

  公开（公告）日：2010-03-31

  This invention discloses a method for preparing a therapeutic or diagnostic complex comprised of a nucleic acid ligand and a lipophilic compound or non-immunogenic, high molecular weight compound by identifying a nucleic acid ligand by SELEX methodology and associating the nucleic acid ligand with a lipophilic compound or a non-immunogenic, high molecular weight compound. The invention further discloses complexes comprising one or more nucleic acid ligands in association with a lipophilic compound or non-immunogenic, high molecular weight compound.

  本发明公开了一种制备由核酸配体和亲油性化合物或非免疫原性高分子量化合物组成的治疗或诊断复合物的方法，该方法通过 SELEX 方法鉴定核酸配体，并将核酸配体与亲油性化合物或非免疫原性高分子量化合物结合。本发明进一步公开了由一个或多个核酸配体与亲脂性化合物或非免疫原性高分子量化合物组成的复合物。
• US6132640A
  申请人：——

  公开号：US6132640A

  公开（公告）日：2000-10-17
• US6407242B1
  申请人：——

  公开号：US6407242B1

  公开（公告）日：2002-06-18